89%of the new coloner

On November 5, Pfizer announced that Pax Robide, an antiviral antiviral drug for the new corona, has prevented 89 % of the severity.

What kind of medicine is this Pax Robide?

A drug that combines new antiviral drugs and existing anti -HIV drugs

This Pax Robide is a combination of a new antiviral drug (PF-07321332) and the existing anti-HIV drug, Ritonabil.

You might think, "Why HIV's medicine ... it doesn't matter to Corona ..."

This ritonabil is used in combination with a type of antiviral drug, a type of protease inhibitory, and has the effect of maintaining the blood concentration of protease inhibitors, and has the name "Ritonabil Boost" that tickles the kitchen.。

For infectious disease doctors, "Ritonabil Boost" is not a problem because it is equivalent to the general public "Kai -Kenken".

It is often used in anticipation of this boost effect, rather than the anti -HIV effect itself, and the "Caletra", which is a combination with an anti -HIV drug called Ritonabil and Ropinaville, was the center of HIV treatment for a while.。

Caletra has been used in the new Corona for a while, as the new coloner is also effective (the effectiveness is now denied).

In this Pax Robide, Ritonabill is used to maintain high blood concentration of PF-07321332.

On the other hand, the antiviral drug called PF-07321332 suppresses the growth of viruses by inhibiting the activity of 3CL protease, an enzyme necessary for duplication of colonovirus.

The new colon virus invades human cells and duplicate themselves.

In this process, multiple proteins are connected at once, but the 3CL protease is separated and separate proteins.

By inhibiting the 3CL protease, the connected proteins cannot be separated and the virus duplication stops.

It is said that not only the original new Coronavirus, which spread from Wuhan City in China, but also various mutant stocks, have antiviral effects.

In the first phase exam, which verified healthy people in Paxlobide, which is a combination of PF-07321332 and Ritonabil, there are no major concerns side effects, and the 2/3 phase exam was the 2/3 phase test.It was started.

Within 3 days of onset, it prevents 89%of severe severe.

The outline of the 2/3 phase exam and the interim analysis results announced this time are as follows.

・ 1219 new Corona patients registered by September 29, 2021

・ For patients with at least one or more severity, mild to moderate patients within 5 days of onset.

・ Of the patients who have been administered to Pax Robide within 3 days of onset, 0 patients are hospitalized by the 28th day after registration..8 % (3/389 people were hospitalized and no death), but those who have been hospitalized or died in the patient who were administered placebo (noble drugs)..0 % (27/385 people were hospitalized and seven later died), and Pax Robide reduced the risk of hospitalization or death by 89 %.

・ The same tendency was found in patients who started treatment within 5 days of onset.

-The adverse events were equivalent to Pax Robide (19%) and placebo (21%), most of which were mild.There were more placebo to cancel the test drug due to serious adverse events and adverse events.

Detailed data has not been announced yet, but this result is considered to be a very effective oral antiviral drug that is very effective.

It is also a safe material that there is no major problem with side effects.

According to the results of this interim analysis, additional registration will be canceled for this study, and urgent approval application will be made in the United States and elsewhere.

Merckk's oral antiviral drug, Mornupirabiru, is urgently approved in the UK, and is expected to be urgently approved in Japan as early as this year.

Increasing the choice of oral antiviral drugs is also important for those who need treatment, and to prepare for resistant viruses that may appear in the future.

The significance of the new colona treatment in the medicine is very large.

Currently, patients with severe and moderate, which do not require severe oxygen administration, can now be used with antibody cocktail therapy (Kashiribi Mab/Im Demab) and monoclonal antibodies of Sotrobi Mab, but both are administered by infusion.It is.

In the fifth wave, it is undoubtedly that the treatment of this monoclonal antibody can be treated not only for inpatients but also for outpatients and home medical treatments, and the number of cases has increased.However, it is undeniable that treatment with infusion is somewhat hurdle in access to medical care.

If it is a medicine, medical professionals will not need to prepare for infusion, and will be able to prescribe promptly at the time of diagnosis.

In the fifth wave, vaccination advanced and the lethal rate decreased significantly, but if Mornupirabiru and Pax Robide are approved, the new colona medical treatment will be simpler and will be expected to be a major progress.

Like Merck's Mornupirabiru, the 2/3 phase test of Pax Robide is also intended for people with a high risk of severe illness, so even if it is urgently approved, the target patient may be a patient that meets this condition.It is expected.

Unfortunately, it is not easy to say that if you are diagnosed with a new colona, you will be able to prescribe it immediately, like an anti -influenza drug Tamiflu.

However, Pax Robide is also conducting clinical research for new colona patients who do not have the risk of severe illness, including vaccination, and if there are drug prices, even young people who do not have good illness can achieve good results in the future.May spread.

In addition, clinical research for rich contacts in the home is also underway, and if the effect of developing the same disease is recognized as antibody cocktail therapy, it will be possible to prevent exposure more easily (only for the time.The best way to prevent is the vaccine).

I think the announcement of Pax Robide will also give the hope that such treatments and prevention may be possible in the not -so -distant future.